A scoping review of alopecia areata and its relationship to COVID-19 vaccinations Authors: Hailey Konisky, Solbie Choi, Aditi Valada, Tyler M. Andriano, Kseniya Kobets Published: 2024 ABSTRACT In response to the COVID-19 pandemic several vaccines were produced, including novel mRNA and viral vector-based vaccines. Though COVID-19 had its own associated dermatological sequelae, the vaccines were associated with a new set of cutaneous side effects, including hypersensitivity reactions, vasculitis, and autoimmune-mediated reactions. Notably, alopecia areata (AA) was reported in several patients closely following a COVID-19 vaccine, especially in those with a personal or family history of AA. A PubMed and Google Scholar search was conducted in July 2024 which resulted in 26 case reports/case series, 1 prospective study, and 3 cross-sectional retrospective chart reviews. Based on our holistic literature review, there is no evidence to support an increased association between COVID-19 vaccination and AA. Despite recent literature highlighting the incidence of de novo and recurrent AA after COVID-19 vaccines, several large retrospective analyses have shown that the overall incidence of AA in vaccinated individuals does not differ from that of historical controls. The potential for de novo AA after COVID-19 vaccine is low and the benefit of being vaccinated far outweighed the risks, especially within the first few years of COVID-19 vaccine rollout. While the decision to get vaccinated is a personal choice, the threat of developing AA secondary to vaccination should not be a deterrent. Introduction In response to the COVID-19 pandemic several vaccines were produced, including novel mRNA and viral vector-based vaccines. Though COVID-19 had its own associated dermatological sequelae, the vaccines were associated with a new set of cutaneous side effects, including hypersensitivity reactions, vasculitis, and autoimmune-mediated reactions [24]. Notably, alopecia areata (AA) was reported in several patients closely following a COVID-19 vaccine, especially in those with a personal or family history of AA. Other vaccines have also been implicated in precipitating AA, including herpes zoster, hepatitis B, and HPV [1, 10]. As of June 8, 2024, the CDC Vaccine Adverse Event Reporting System (VAERS) logged 467 reports of AA after any brand of COVID-19 vaccine. A recent meta-analysis of 51 patients noted that 53% of patients experienced de novo AA after COVID-19 vaccination [33]. The purpose of this review is to provide a comprehensive overview of studies describing COVID-19 vaccine-associated AA to further enrich our understanding of this phenomenon. Methods A PubMed and Google Scholar search was conducted in July 2024 using combinations of the terms “alopecia areata” AND “vaccine”, “alopecia areata” AND “SARS-CoV-2 vaccine”, and “hair loss” AND “COVID-19 vaccine”. Papers were excluded if they were not in English, were review papers, discussed hair loss due to COVID-19 disease or hair loss other than alopecia areata, or discussed a vaccine other than COVID-19. This resulted in 26 case reports/case series, 1 prospective study, and 3 cross-sectional retrospective chart reviews. Results Cross-sectional studies A 2022 nationwide assessment in South Korea compared over 3 million vaccinated individuals to matched controls. Overall, there was not an increased incidence of any autoimmune disease post- COVID-19 vaccination. They noted that the incidence of AA, alopecia totalis, and cicatricial alopecia did not differ significantly between vaccinated individuals and historical controls. The authors postulate that the association of increased autoimmune disease after the COVID-19 vaccine is a result of intensive observation of patients and physicians after administration of a new vaccine [19]. A retrospective review conducted in Italy reviewed patients at a hair loss clinic from 2021 to 2022. They found that 16% of patients at this clinic had AA, with no statistical difference from pre-COVID historical controls (p = 0.244). Twenty-four patients were identified as having AA after COVID-19 vaccination. Pfizer BNT162b2 was the most common vaccine amongst these individuals (62%), and onset of hair loss was on average 5.2 weeks from vaccination of any type. The average age was 39.1, and there was a strong female predominance (83%). In 22 of these patients, the hair loss was a relapse of prior AA. Half of the patients had a history of other autoimmune diseases. This study overall highlights that while there was not an increased incidence in AA because of the COVID-19 vaccine, female patients with a history of AA or other autoimmune conditions are at a higher risk of developing relapse of AA within 16 weeks of vaccination [29]. Another retrospective cohort study from California, USA, analyzed 73 cases of AA diagnosed in their clinic between December 2020 and February 2023 and compared to matched controls. Thirty-seven of these patients received 1–2 doses of the COVID-19 vaccine prior to AA onset. In contrast to other studies, the authors found that the odds of developing AA after vaccination was decreased (OR 0.58, 95% CI = 0.35–0.94). The risk of AA was also found to be significantly lower in females. The authors acknowledge limitations to this study, but postulate that this finding could be due to modulation of regulatory T-cells after vaccination which mitigates autoimmune activity, or due to reduced anxiety and stress after being vaccinated during a global pandemic [8]. Prospective study A prospective study explored the causality, immune mechanism, and clinical manifestations of immune-mediated hair loss associated with COVID-19 vaccination in 27 patients with a new-onset AA following vaccination compared to 106 vaccinated controls. The mean age of the AA group was 38.2 ± 15.8 years versus 43.7 ± 15.9 years in controls. Of those with AA, 40.7% received the mRNA-1273 vaccine, 29.6% received the BNT162b2 vaccine, 25.9% received the AZD1222 vaccine, and 3.7% received the MVC-COV1901 vaccine. Sixteen patients (59.3%) experienced symptoms after the 2nd dose of the vaccine, 5 patients after the 3rd/4th dose (18.5%), and 6 patients after the 1st dose (22.2%). The mean time from vaccination to AA onset was 27.6 ± 19.7 days (range: 2–65 days), with time to symptom onset inversely correlating with the number of doses. Pertinent history of autoimmune diseases including atopic dermatitis (7.4%, n = 2), urticaria/chronic urticaria (7.4%, n = 2), pompholyx (3.7%), ankylosing spondylitis (3.7%), and androgenetic alopecia (3.7%) were noted. There were no significant differences between groups regarding autoimmune history. Laboratory data revealed significantly increased antinuclear antibody (ANA) level (OR = 6.4, 95% CI = 1.6–25.8), total IgE level (OR = 8.0, 95% CI = 2.8–23.1), and eosinophil count (> 5%) (OR = 3.8, 95% CI = 1.2–12.1) in the AA groups versus controls. There were no cytokines, chemokines, or inflammatory proteins levels that correlated with the severity of AA. Eleven (40.7%) patients in the AA group were categorized as severe using the SALT scale, and 16 (59.3%) were categorized as having mild to moderate AA. Twenty-five of the 27 AA patients were on multiple agent therapy. Topical corticosteroids were the most common form of treatment (n = 24), and over 81.5% were on at least one systemic immunosuppressive agent. JAK inhibitors (tofacitinib, baricitinib) were administered to 6 patients with severe and recalcitrant AA. Of the AA group, 14 patients reached complete remission after > 5 months of follow-up. The average treatment duration of this group was 153.2 ± 57.3 days [31]. This study demonstrates that individuals with elevated blood markers of autoimmunity are more likely to have new or recurring AA after COVID-19 vaccination. Selected case reports Case reports described patients developing AA after various vaccine formulations: Pfizer (n = 40), Moderna (n = 14), AstraZeneca (n = 14), and Sinopharm (n = 5). There was a predominance of females affected (n = 51/73), which is typical for autoimmune conditions [3]. Comorbid AA or thyroiditis was often observed, in addition to a personal or family history of autoimmunity. There was a recurrence or worsening of prior AA within 21 patients who reported a personal history of AA. Onset of AA after the vaccine varied from days to months. Treatments such as clobetasol, 5% minoxidil, intralesional triamcinolone (ILTAC), tofacitinib citrate, triamcinolone, oral prednisolone, hydroxychloroquine, dexamethasone, corticosteroids, and JAK inhibitors were attempted, but did not always show effective results. A total of 73 individuals with post-vaccination AA, either de novo or recurrent, were described in case series or reports (Table 1). Herein, we highlight a select few. Recurrence of alopecia areata Abdalla et al. presented a 63-year-old female with a history of hypothyroidism, prediabetes, thalassemia trait, and allergic rhinitis. She experienced a recurrence of AA after 32 years of remission 2 weeks after receiving the first dose of the BNT162b2 vaccine, initially presenting with patchy hair loss which progressed to AA universalis within 6 weeks of the first dose [1]. Scollan et al. presented a 28-year-old woman with a history of AA and Hashimoto thyroiditis who reported loss of all scalp and body hair within 1 week after her 2nd dose of the BNT162b2 series. Treatment with intralesional triamcinolone (ILTAC) and platelet-rich plasma (PRP) therapy provided little improvement. The patient was subsequently prescribed tofacitinib citrate 10 mg twice a day [26]. Rossi et al. presented a 29-year-old female with a medical history of patchy AA, previously treated with topical and systemic steroids with complete regrowth. Two weeks following her first dose of the AZD1222 vaccine, she presented with sudden generalized hair loss on the scalp with a partial loss of eyebrows and eyelashes. Trichoscopy revealed multiple black dots and broken hairs. The patient was subsequently diagnosed with acute AA and began a treatment regimen of topical steroids with a follow-up scheduled in 4 weeks [25]. De novo alopecia areata May Lee et al. presented an 80-year-old male with no relevant past medical history who experienced rapid beard hair loss on his left cheek and upper lip and scalp hair loss 7 days after his first dose of the BNT162b2 vaccine. AA was diagnosed via a positive pull test and trichoscopy examination showing cadaveric and exclamation point hairs. His AA worsened after the second dose of the vaccine [23]. Hernandez Arroyo et al. presented a 59-year-old male patient with no family or personal history of autoimmune disease and a remote past medical history of COVID-19 who presented with excessive hair loss 17 days following the booster of the AZD1222 vaccine. He was diagnosed with AA universalis. He was treated with mesotherapy and pulses of dexamethasone and clobetasol propionate 0.5% topically with 15% improvement in regrowth [16]. Iwata et al. presented a Japanese female patient in her 40s with no relevant history of AA who developed loss of hair on her scalp, eyebrows, eyelashes, axilla, pubis, arms, and legs one week after her first dose of the mRNA-1273 vaccine. She was treated with prednisone, excimer lamp therapy, oral cepharanthine, and monoammonium glycyrrhizinate but showed minimal improvement [18]. Discussion Based on our holistic literature review, there is no evidence to support an increased association between COVID-19 vaccination and AA. Recent meta-analysis causality assessments noted that only 20% of cases were classified as “consistent with causal association to immunization” versus 53% that were “coincidentally associated” [33]. The BNT162b2 (Pfizer) vaccine was the most implicated in the literature; however, this may be due to lead-time bias since it was the first FDA-approved COVID-19 vaccine. AA after infection or vaccination against COVID-19 is thought to be due to molecular mimicry, since the spike protein of the virus is closely related to some human proteins [24]. AA is a multifactorial autoimmune disease mediated by T-cells that attack the hair follicle causing loss of immune privilege [31]. One prospective study identified that vaccine ingredients such as PEG2000 and polysorbate 80 triggered a similar immune response as exposure to the SARS-CoV-2 spike protein. Additionally, patients with vaccine-induced AA had significantly higher levels of cytotoxic proteins from CD8 + T-cells that may cause cell apoptosis in the hair follicle and trigger the autoimmune response [31]. It is postulated that the vaccine may also quickly increase interferon, which upregulates IL-12 and IL-23 causing inflammation [10]. Despite recent literature highlighting the incidence of de novo and recurrent AA after COVID-19 vaccines, several large retrospective analyses have shown that the overall incidence of AA in vaccinated individuals does not differ from that of historical controls. Those authors concluded that the potential for de novo AA after COVID-19 vaccine is low and that the benefit of being vaccinated far outweighed the risks, especially within the first few years of COVID-19 vaccine rollout. While the decision to get vaccinated is a personal choice, the threat of developing AA secondary to vaccination should not be a deterrent. Conclusions Overall, studies have shown that vaccination against COVID-19 does not increase the incidence of AA. However, variables that may predispose individuals to AA catalyzed by this vaccine include female sex, personal history of AA, and personal or family history of autoimmunity. The risk of AA secondary to COVID-19 vaccination remains low when compared to the individual and public health benefits. Future research on AA and its relationship to vaccines, including the COVID-19 vaccine, are warranted to further elucidate the mechanism in which this phenomenon occurs and how to best counsel patients. Table 1Summary of cases described in the literature from March 2020–July 2024PMIDPatientsType of SARS-CoV-2vaccineHistory of autoimmunityTime from vaccine to hair lossExtent of AASignificant family historyClinical presentationTreatment/ OutcomeCase reports 35975094 [1]n = 165 F1st dose(BNT162b2)Hashimoto’s ThyroiditisAllergic rhinitisAA 32 years ago2 weeks after 1st dosePAA → AAUN/AComplete loss of scalp, facial, and body hair after 6 weeksN/A 36239007 [21]n = 17 F2nd dose (BNT162b2)AA20 days after 2nd dosePAAN/ANonscarring alopecia patch on occipital region with foci of hair regrowthN/A 35107173 [23]n = 180 M1st dose(BNT162b2)N/A7 days after 1st doseAAU→ AATN/ABeard hair loss on left cheekDiffuse hair loss in scalpComplete hair loss in scalp2 month follow up showed AATFailed: foam clobetasolFailed: a topical immunotherapy with squaric acid dibutylester combined withtopical 5% minoxidil. 35223675 [12]n = 131 M2nd dose (BNT162b2)N/A1 day after 2nd doseAAUN/AMultiple circular patches of alopecia on occipital, bilateral parieto-temporal, front area with beardN/A 34559937 [9]n = 132 F(AZD1222)Mild attack of AA but stable for 6 yearsprevious COVID-19 1 year priorFew days after dosePAAN/ASharply demarcated patchy hair loss on scalp without scarring or scaringN/A 35642187 [17]n = 151 F2nd dose(AZD1222)N/A3 daysAAUN/AIntense pruritus of scalp with subsequent complete loss of all body hair in 3 weeksClobetasol propionate ointment -Intralesional triamcinolone acetonide 10 mg/mL 35770484 [13]n = 127 FBooster(BNT162b2)Systemic lupus erythematosus after AZD1222 one year prior15 days after doseAAN/Adiffuse alopecia, bx proven AAN/A(Only treatment of SLE listed − 80 mg/day oral prednisolone andhydroxychloroquine 400 mg/day.) 35379574 [28]n = 142 M1st dose (AZD1222)N/A3 weeks after 1st dosePAAN/AWell demarcated patches of hair loss (1–10 cm) on scalp, without scarring or scalingLargest patch at vertexILTAC (10 mg/dL) 37441583 [18]n = 140s F(mRNA-1273)N/A1 week after 1st doseAAT, AAUN/AHair loss on head, eyebrows, eyelashes, axilla, pubis, arms, legsFailed: Oral prednisone, oral cepharanthin, monoammonium glycyrrhizinateLittle improvement: Excimer lamp treatment 36856386 [32]n = 120 FBooster(Sinopharm)N/A2 weeks after booster dosePAAN/ASeveral patches of non-scarring alopecia on her scalpSALT score: 30Topical and oral steroids No PMID Matsuda et al. 2023 [22]n = 137 F(BNT162b2)N/A22 days after 1st dosePAA→ AATN/ACoin-sized patches of hair loss on scalp, progressing to greater area on scalpSigns of hair growth on day 120 with topical betamethasone butyrate propionate lotionAlmost full recovery on day 310 35571458 [20]n = 161 F2nd dose (BNT162b2)N/A1 weekPAAN/A4 areas of scalp patchy hair loss, 2 punch biopsies revealed follicular miniaturization, catagen/telogen shift, peribulbar/lymphocytic inflammatory infiltrate0.05% topical fluocinonide solution, topical minoxidil for 1 month, subsequent 0.1% tacrolimus ointment and 5% minoxidil solution for additional 5 monthsIntralesional acetonide 2.5 mg/cc administered once a month for 3 consecutive monthsImprovement observed 1 month after treatment, full regrowth in four areas observed at 4 month follow upNo relapse in hair loss observed after Pfizer booster vaccine or 8 month follow up 37192849 [30]n = 134 F2nd dose (AZD1222)N/A4 weeks after 2nd doseAAN/AScalp hair loss over entire scalp, hair pull test revealed massive hair loss after slight pullIneffective: Oral prednisolone 25–40 mg daily for approximately 1 monthSubsequent: double-spin platelet-rich plasma (PRP) therapy from 80mL of whole blood, second dose of PRP (160mL whole blood) 6 weeks later; Hair regrowth was observed and hair loss stabilized after two doses of PRP treatment; Complete recovery after 6 courses of PRP treatment 36942081 [2]n = 144 M2 doses (mRNA-1273)N/A2 weeks after 1st doseAAN/ASARS-CoV2 infection followed by vaccination 3 months laterPatches of scalp hair loss following first dose; Diffuse hair loss (scalp, eyelashes, bear hair, eyebrows) following second doseFacial and scalp hair regrowth 2 weeks after second dose followed by subsequent Marie Antoinette syndrome 3 days after regrowth. New-onset arm and lower leg hair lossIneffective treatment following first dose: 50 mg PO Prednisone daily for 5 days, betamethasone valerate 0.05% lotion (1 month discontinue due to dermatitis, abscesses) 35757867 [4]n = 133 F2 doses (Sinopharm)N/A4 weeks after 2nd doseAAN/ADelineated hair loss patches with no scarring or scaling compromising < 50% of scalpIntralesional and topical corticosteroids1-month follow-up to treatment revealed stable lesions and signs of regrowthCase Series 35789521 [7]n = 21: 29 M2: 26 F1: (AZD1222)2:(BNT162b2)1: AA2: AA1: 1 week after 2nd dose2: 2 weeks after 2nd dose1: PAA2: PAA→ AAUN/A1: Balding patches on scalp2: Initial diffused hair loss on scalp and body, progressing to areas of eyebrows and eyelash1 Failed: pulse steroid therapy2 Failed: pulse steroid therapy 36172335 [14]n = 21: 23 F2: 26 F1: (AZD1222)2: (AZD1222)1: N/A2: AA1: 1 week after 1st dose2: 2 weeks after 2nd dose1: PAA→AAU2: PAA→ AATN/A1: Myalgia and local hair scalp, progressing to entire loss of hair in scalp and eyebrows after 3 weeks2: Patchy hair loss in scalp progressing to total hair loss in scalp after 1 month1: Systemic cortisone (oral prednisone, 300 mg) for three months2: Systemic cortisone (oral prednisone, 300 mg) for three months 36926281 [15]n = 54 F:Mean Age 32.41 M: 31y2 patients: (BNT162b2)3 patients: (mRNA-1273)AA (remission 1.8 years ± 1.48)Mean time after 1st dose: 2 weeks ± 0.7AATN/AHair loss was 25% greater than at the beginningFailed: minoxidil 5% 1 mL bis in die, topical clobetasol, topical growth factors, and intralesional triamcinolone 3:1 34931171 [26]n = 9Mean Age: 35.91:33 F2:57 F3: 62 F4: 28 F5: 29 F6: 22 M7 :15 M8: 61 M9: 16 M1:mRNA-12732: BNT162b23:mRNA-12734: BNT162b25: BNT162b26: BNT162b27: BNT162b28: BNT162b29: BNT162b21: N/A2: remote history AA3: remote Hx AA4: AA, Hashimoto thyroiditis5: Elevated levelsof thyroglobulinantibody andthyroid peroxidaseAntibody6: Elevated thyroidantibody, normalthyroid functionTests7: NA8: Joint pain hydroxychloroquine9: NA1: 2 months after 2nd dose2: 4 months after 2nd dose3: 2 months after 2nd dose4: 1 week after 2nd dose5: 1 week after 2nd dose6: 1 month after 2nd dose7: Within 1 week after 2nd dose8: 2 weeks after 1st dose9: Within 1–2 weeks after 1st dose1: PAA2: AAT3: AAU4: AAU5: PAA6: PAA7: PAA8: AAT9: PAA1: Brother AA7: Grandmother with Hashimoto thyroiditis, sister w/ elevated thyroid antibody1: Large patches of nonscarring alopecia with foci of hair regrowth2: widespread nonscarring alopecia of scalp with foci of hair regrowth3: alopecia universalis4: Alopecia universalis5: Two patches ofnonscarring alopeciaof the scalp with areasof regrowth6: Patches of nonscarringalopecia; 30% hair lossfrom scalp, 80% hairloss from beard7: Two patches ofnonscarring alopeciaof the scalp8: Alopecia totalis9: Patches of nonscarringalopecia with 70% lossof scalp hair; sparseeyebrows andeyelashes1: 4 treatments intralesional triamcinolone (ILTACT), pimecrolimus 1% cream, clobetasol 0.05%foam, subsequent tofacitinib citrate 5 mg2: Failed: attempted trials tofacitinib 2%/clobetasol 0.05% ointment/clobetasol solution compounded with little improvementSubsequent Tx: tofacitinib citrate 5 mg3: tofacitinib citrate 10 mg 2x/day, bimatoprost 0.03% eye drops4: Failed: PRP therapy (little improvement)Subsequent: tofacitinib citrate 10 mg 2x/day5: NA previous, subsequent ILTAC6: Failed previous: ILTACsubsequent Tofacitinib citrate10 mg twice a day7: ILTAC8: Pending possible trialof oral tofacitinibcitrate9: Failed: ILTACSubsequent: Tofacitinib citrate10 mg twice a day 35182005 [6]n = 34: 41 F5: 24 M6: 21 F4: 1st doseBNT162b25: 1st doseBNT162b26: 1st dose mRNA-12735: Previous episodes of AA in pediatric age.6: Allergic Asthma4: 1 week after dose5: 1 week after dose6: 2 weeks after dose4: PAA5: PAA6: PAA5: Previous episodes of AA in pediatric age. Sister affected by AGA + AAI4:Patchy (multiple patches) SALT: 26; Complete regrowth in 3 months5:AA totalis SALT: 100; Alopecia universalis.5: Intramuscular triamcinolone 40 mg/dL every 4 weeks for 3 sessions + clobetasol propionate 0.05% under occlusion 5 times/week6:3 sessions of monthly injection of intralesional triamcinolone 10 g/mL 36851320 [16]n = 31: 27 F2: 51 F5: 59 MBooster (3rd dose)(BNT162b2, Sinopharm, andAZD1222)1: AAU, Polycystic Ovary, COVID-192: N/A3: N/A1: 8 days after dose2: 3 days after dose5: 17 days after dose1: AAU2: AAU5: AAU2: grandmother with hypothyroidism1:Alopecia universalis5:Alopecia universalis1: Mesotherapy and pulses of dexamethasone and Clobetasolpropionate 0.5% topical5: Mesotherapy and pulses of dexamethasone and Clobetasol propionate 0.5% topical 34741583 [25]n = 31: 76 F2: 59 F3: 29 F1: BNT162b22: AZD12223: AZD12221: AA2: AA, autoimmune thyroiditis3: AA1: 2 weeks2: 3 weeks3: 2 weeks1: AA2: AA3: AAN/A1: Widespread hair loss of scalp2: Single oval bald patch at vertex3: Generalized hair loss of scalp1: topical steroids2: topical steroids, oral Vitamin D3: steroids 36146545 [29]n = 24 (20 F, 4 M)Mean Age: 39.115 with 2–3 doses BNT162b25 with 2 doses mRNA-12734 with 2 doses AZD122212 with Autoimmune History9 with Hashimoto thyroiditis2 with Celiac disease1 with Connective tissue diseaseBNT162b2- 5.7 weeksmRNA-1273- 6.4 weeksAZD1222- 2.2 weeksPAA- (n = 14)AAT (n = 6)AAU (n = 4)N/AN/A76% responded to treatment with topical and/or systemic treatment. 35716105 [27]n = 21–74 M2–37 M1- Sinopharm 1st dose2- Sinopharm 2nd doseN/A1: 2 days2: 6 days1: PAA2:PAA→AATN/AN/AILK 36035747 [5]n = 31–33 F2–27 M3–32 M1–3 doses BNT162b22-2 doses BNT162b23-2 doses mRNA-1273N/A1: 2 weeks after first dose, exacerbated after second dose2: 2 weeks after second dose3: 2 weeks after first dose1: AA2: AA3: AAN/A1: near complete, widespread loss of scalp hair 3 months following second dose (SALT increase 33)2: Patchy Scalp Hair Loss3: Patchy Scalp Hair lossPre-vaccination JAKi therapy continued, no changes to systemic therapy 36483229 [11]n = 21–42 M2–18 M1:3 doses BNT162b22: 2 doses BNT162b21: AA2: PAA1: 4 weeks after second dose, worsened after third dose2: 20 days after first dose, worsened progressively after second dose1: AT2: ATN/A1: complete loss of whole scalp hairs2: pre-existing AA patches being treated, experienced worsening of patches being treated following first dose; after second dose, widespread hair loss on whole scalp, positive pull test1: High potency steroids2: High potency steroidsChAdOx1 nCoV-19 = AZD1222 = AstraZeneca Recombinant VaccinemRNA-1273 = Spikevax®= Moderna mRNABNT162b2 = Comirnaty®= Pfizer BioNTech mRNAMVC-COV1901 = Medigen Recombinant VaccineSinopharm = CoronaVac®= inactivated virus M Male, F Female, PAA Patchy alopecia areata, AAT Alopecia areata totalis, AAU Alopecia areata universalis, AA Alopecia areata, N/A Not applicable, SALT The severity of alopecia tool Table 1Summary of cases described in the literature from March 2020–July 2024PMIDPatientsType of SARS-CoV-2vaccineHistory of autoimmunityTime from vaccine to hair lossExtent of AASignificant family historyClinical presentationTreatment/ OutcomeCase reports 35975094 [1]n = 165 F1st dose(BNT162b2)Hashimoto’s ThyroiditisAllergic rhinitisAA 32 years ago2 weeks after 1st dosePAA → AAUN/AComplete loss of scalp, facial, and body hair after 6 weeksN/A 36239007 [21]n = 17 F2nd dose (BNT162b2)AA20 days after 2nd dosePAAN/ANonscarring alopecia patch on occipital region with foci of hair regrowthN/A 35107173 [23]n = 180 M1st dose(BNT162b2)N/A7 days after 1st doseAAU→ AATN/ABeard hair loss on left cheekDiffuse hair loss in scalpComplete hair loss in scalp2 month follow up showed AATFailed: foam clobetasolFailed: a topical immunotherapy with squaric acid dibutylester combined withtopical 5% minoxidil. 35223675 [12]n = 131 M2nd dose (BNT162b2)N/A1 day after 2nd doseAAUN/AMultiple circular patches of alopecia on occipital, bilateral parieto-temporal, front area with beardN/A 34559937 [9]n = 132 F(AZD1222)Mild attack of AA but stable for 6 yearsprevious COVID-19 1 year priorFew days after dosePAAN/ASharply demarcated patchy hair loss on scalp without scarring or scaringN/A 35642187 [17]n = 151 F2nd dose(AZD1222)N/A3 daysAAUN/AIntense pruritus of scalp with subsequent complete loss of all body hair in 3 weeksClobetasol propionate ointment -Intralesional triamcinolone acetonide 10 mg/mL 35770484 [13]n = 127 FBooster(BNT162b2)Systemic lupus erythematosus after AZD1222 one year prior15 days after doseAAN/Adiffuse alopecia, bx proven AAN/A(Only treatment of SLE listed − 80 mg/day oral prednisolone andhydroxychloroquine 400 mg/day.) 35379574 [28]n = 142 M1st dose (AZD1222)N/A3 weeks after 1st dosePAAN/AWell demarcated patches of hair loss (1–10 cm) on scalp, without scarring or scalingLargest patch at vertexILTAC (10 mg/dL) 37441583 [18]n = 140s F(mRNA-1273)N/A1 week after 1st doseAAT, AAUN/AHair loss on head, eyebrows, eyelashes, axilla, pubis, arms, legsFailed: Oral prednisone, oral cepharanthin, monoammonium glycyrrhizinateLittle improvement: Excimer lamp treatment 36856386 [32]n = 120 FBooster(Sinopharm)N/A2 weeks after booster dosePAAN/ASeveral patches of non-scarring alopecia on her scalpSALT score: 30Topical and oral steroids No PMID Matsuda et al. 2023 [22]n = 137 F(BNT162b2)N/A22 days after 1st dosePAA→ AATN/ACoin-sized patches of hair loss on scalp, progressing to greater area on scalpSigns of hair growth on day 120 with topical betamethasone butyrate propionate lotionAlmost full recovery on day 310 35571458 [20]n = 161 F2nd dose (BNT162b2)N/A1 weekPAAN/A4 areas of scalp patchy hair loss, 2 punch biopsies revealed follicular miniaturization, catagen/telogen shift, peribulbar/lymphocytic inflammatory infiltrate0.05% topical fluocinonide solution, topical minoxidil for 1 month, subsequent 0.1% tacrolimus ointment and 5% minoxidil solution for additional 5 monthsIntralesional acetonide 2.5 mg/cc administered once a month for 3 consecutive monthsImprovement observed 1 month after treatment, full regrowth in four areas observed at 4 month follow upNo relapse in hair loss observed after Pfizer booster vaccine or 8 month follow up 37192849 [30]n = 134 F2nd dose (AZD1222)N/A4 weeks after 2nd doseAAN/AScalp hair loss over entire scalp, hair pull test revealed massive hair loss after slight pullIneffective: Oral prednisolone 25–40 mg daily for approximately 1 monthSubsequent: double-spin platelet-rich plasma (PRP) therapy from 80mL of whole blood, second dose of PRP (160mL whole blood) 6 weeks later; Hair regrowth was observed and hair loss stabilized after two doses of PRP treatment; Complete recovery after 6 courses of PRP treatment 36942081 [2]n = 144 M2 doses (mRNA-1273)N/A2 weeks after 1st doseAAN/ASARS-CoV2 infection followed by vaccination 3 months laterPatches of scalp hair loss following first dose; Diffuse hair loss (scalp, eyelashes, bear hair, eyebrows) following second doseFacial and scalp hair regrowth 2 weeks after second dose followed by subsequent Marie Antoinette syndrome 3 days after regrowth. New-onset arm and lower leg hair lossIneffective treatment following first dose: 50 mg PO Prednisone daily for 5 days, betamethasone valerate 0.05% lotion (1 month discontinue due to dermatitis, abscesses) 35757867 [4]n = 133 F2 doses (Sinopharm)N/A4 weeks after 2nd doseAAN/ADelineated hair loss patches with no scarring or scaling compromising < 50% of scalpIntralesional and topical corticosteroids1-month follow-up to treatment revealed stable lesions and signs of regrowthCase Series 35789521 [7]n = 21: 29 M2: 26 F1: (AZD1222)2:(BNT162b2)1: AA2: AA1: 1 week after 2nd dose2: 2 weeks after 2nd dose1: PAA2: PAA→ AAUN/A1: Balding patches on scalp2: Initial diffused hair loss on scalp and body, progressing to areas of eyebrows and eyelash1 Failed: pulse steroid therapy2 Failed: pulse steroid therapy 36172335 [14]n = 21: 23 F2: 26 F1: (AZD1222)2: (AZD1222)1: N/A2: AA1: 1 week after 1st dose2: 2 weeks after 2nd dose1: PAA→AAU2: PAA→ AATN/A1: Myalgia and local hair scalp, progressing to entire loss of hair in scalp and eyebrows after 3 weeks2: Patchy hair loss in scalp progressing to total hair loss in scalp after 1 month1: Systemic cortisone (oral prednisone, 300 mg) for three months2: Systemic cortisone (oral prednisone, 300 mg) for three months 36926281 [15]n = 54 F:Mean Age 32.41 M: 31y2 patients: (BNT162b2)3 patients: (mRNA-1273)AA (remission 1.8 years ± 1.48)Mean time after 1st dose: 2 weeks ± 0.7AATN/AHair loss was 25% greater than at the beginningFailed: minoxidil 5% 1 mL bis in die, topical clobetasol, topical growth factors, and intralesional triamcinolone 3:1 34931171 [26]n = 9Mean Age: 35.91:33 F2:57 F3: 62 F4: 28 F5: 29 F6: 22 M7 :15 M8: 61 M9: 16 M1:mRNA-12732: BNT162b23:mRNA-12734: BNT162b25: BNT162b26: BNT162b27: BNT162b28: BNT162b29: BNT162b21: N/A2: remote history AA3: remote Hx AA4: AA, Hashimoto thyroiditis5: Elevated levelsof thyroglobulinantibody andthyroid peroxidaseAntibody6: Elevated thyroidantibody, normalthyroid functionTests7: NA8: Joint pain hydroxychloroquine9: NA1: 2 months after 2nd dose2: 4 months after 2nd dose3: 2 months after 2nd dose4: 1 week after 2nd dose5: 1 week after 2nd dose6: 1 month after 2nd dose7: Within 1 week after 2nd dose8: 2 weeks after 1st dose9: Within 1–2 weeks after 1st dose1: PAA2: AAT3: AAU4: AAU5: PAA6: PAA7: PAA8: AAT9: PAA1: Brother AA7: Grandmother with Hashimoto thyroiditis, sister w/ elevated thyroid antibody1: Large patches of nonscarring alopecia with foci of hair regrowth2: widespread nonscarring alopecia of scalp with foci of hair regrowth3: alopecia universalis4: Alopecia universalis5: Two patches ofnonscarring alopeciaof the scalp with areasof regrowth6: Patches of nonscarringalopecia; 30% hair lossfrom scalp, 80% hairloss from beard7: Two patches ofnonscarring alopeciaof the scalp8: Alopecia totalis9: Patches of nonscarringalopecia with 70% lossof scalp hair; sparseeyebrows andeyelashes1: 4 treatments intralesional triamcinolone (ILTACT), pimecrolimus 1% cream, clobetasol 0.05%foam, subsequent tofacitinib citrate 5 mg2: Failed: attempted trials tofacitinib 2%/clobetasol 0.05% ointment/clobetasol solution compounded with little improvementSubsequent Tx: tofacitinib citrate 5 mg3: tofacitinib citrate 10 mg 2x/day, bimatoprost 0.03% eye drops4: Failed: PRP therapy (little improvement)Subsequent: tofacitinib citrate 10 mg 2x/day5: NA previous, subsequent ILTAC6: Failed previous: ILTACsubsequent Tofacitinib citrate10 mg twice a day7: ILTAC8: Pending possible trialof oral tofacitinibcitrate9: Failed: ILTACSubsequent: Tofacitinib citrate10 mg twice a day 35182005 [6]n = 34: 41 F5: 24 M6: 21 F4: 1st doseBNT162b25: 1st doseBNT162b26: 1st dose mRNA-12735: Previous episodes of AA in pediatric age.6: Allergic Asthma4: 1 week after dose5: 1 week after dose6: 2 weeks after dose4: PAA5: PAA6: PAA5: Previous episodes of AA in pediatric age. Sister affected by AGA + AAI4:Patchy (multiple patches) SALT: 26; Complete regrowth in 3 months5:AA totalis SALT: 100; Alopecia universalis.5: Intramuscular triamcinolone 40 mg/dL every 4 weeks for 3 sessions + clobetasol propionate 0.05% under occlusion 5 times/week6:3 sessions of monthly injection of intralesional triamcinolone 10 g/mL 36851320 [16]n = 31: 27 F2: 51 F5: 59 MBooster (3rd dose)(BNT162b2, Sinopharm, andAZD1222)1: AAU, Polycystic Ovary, COVID-192: N/A3: N/A1: 8 days after dose2: 3 days after dose5: 17 days after dose1: AAU2: AAU5: AAU2: grandmother with hypothyroidism1:Alopecia universalis5:Alopecia universalis1: Mesotherapy and pulses of dexamethasone and Clobetasolpropionate 0.5% topical5: Mesotherapy and pulses of dexamethasone and Clobetasol propionate 0.5% topical 34741583 [25]n = 31: 76 F2: 59 F3: 29 F1: BNT162b22: AZD12223: AZD12221: AA2: AA, autoimmune thyroiditis3: AA1: 2 weeks2: 3 weeks3: 2 weeks1: AA2: AA3: AAN/A1: Widespread hair loss of scalp2: Single oval bald patch at vertex3: Generalized hair loss of scalp1: topical steroids2: topical steroids, oral Vitamin D3: steroids 36146545 [29]n = 24 (20 F, 4 M)Mean Age: 39.115 with 2–3 doses BNT162b25 with 2 doses mRNA-12734 with 2 doses AZD122212 with Autoimmune History9 with Hashimoto thyroiditis2 with Celiac disease1 with Connective tissue diseaseBNT162b2- 5.7 weeksmRNA-1273- 6.4 weeksAZD1222- 2.2 weeksPAA- (n = 14)AAT (n = 6)AAU (n = 4)N/AN/A76% responded to treatment with topical and/or systemic treatment. 35716105 [27]n = 21–74 M2–37 M1- Sinopharm 1st dose2- Sinopharm 2nd doseN/A1: 2 days2: 6 days1: PAA2:PAA→AATN/AN/AILK 36035747 [5]n = 31–33 F2–27 M3–32 M1–3 doses BNT162b22-2 doses BNT162b23-2 doses mRNA-1273N/A1: 2 weeks after first dose, exacerbated after second dose2: 2 weeks after second dose3: 2 weeks after first dose1: AA2: AA3: AAN/A1: near complete, widespread loss of scalp hair 3 months following second dose (SALT increase 33)2: Patchy Scalp Hair Loss3: Patchy Scalp Hair lossPre-vaccination JAKi therapy continued, no changes to systemic therapy 36483229 [11]n = 21–42 M2–18 M1:3 doses BNT162b22: 2 doses BNT162b21: AA2: PAA1: 4 weeks after second dose, worsened after third dose2: 20 days after first dose, worsened progressively after second dose1: AT2: ATN/A1: complete loss of whole scalp hairs2: pre-existing AA patches being treated, experienced worsening of patches being treated following first dose; after second dose, widespread hair loss on whole scalp, positive pull test1: High potency steroids2: High potency steroidsChAdOx1 nCoV-19 = AZD1222 = AstraZeneca Recombinant VaccinemRNA-1273 = Spikevax®= Moderna mRNABNT162b2 = Comirnaty®= Pfizer BioNTech mRNAMVC-COV1901 = Medigen Recombinant VaccineSinopharm = CoronaVac®= inactivated virus M Male, F Female, PAA Patchy alopecia areata, AAT Alopecia areata totalis, AAU Alopecia areata universalis, AA Alopecia areata, N/A Not applicable, SALT The severity of alopecia tool Summary of cases described in the literature from March 2020–July 2024 n = 1 65 F 1st dose (BNT162b2) Hashimoto’s Thyroiditis Allergic rhinitis AA 32 years ago n = 1 7 F n = 1 80 M 1st dose (BNT162b2) Beard hair loss on left cheek Diffuse hair loss in scalp Complete hair loss in scalp 2 month follow up showed AAT Failed: foam clobetasol Failed: a topical immunotherapy with squaric acid dibutylester combined with topical 5% minoxidil. n = 1 31 M n = 1 32 F Mild attack of AA but stable for 6 years previous COVID-19 1 year prior n = 1 51 F 2nd dose (AZD1222) n = 1 27 F Booster (BNT162b2) N/A (Only treatment of SLE listed − 80 mg/day oral prednisolone and hydroxychloroquine 400 mg/day.) n = 1 42 M Well demarcated patches of hair loss (1–10 cm) on scalp, without scarring or scaling Largest patch at vertex n = 1 40s F Failed: Oral prednisone, oral cepharanthin, monoammonium glycyrrhizinate Little improvement: Excimer lamp treatment n = 1 20 F Booster (Sinopharm) Several patches of non-scarring alopecia on her scalp SALT score: 30 No PMID Matsuda et al. 2023 [22] n = 1 37 F Signs of hair growth on day 120 with topical betamethasone butyrate propionate lotion Almost full recovery on day 310 n = 1 61 F 0.05% topical fluocinonide solution, topical minoxidil for 1 month, subsequent 0.1% tacrolimus ointment and 5% minoxidil solution for additional 5 months Intralesional acetonide 2.5 mg/cc administered once a month for 3 consecutive months Improvement observed 1 month after treatment, full regrowth in four areas observed at 4 month follow up No relapse in hair loss observed after Pfizer booster vaccine or 8 month follow up n = 1 34 F Ineffective: Oral prednisolone 25–40 mg daily for approximately 1 month Subsequent: double-spin platelet-rich plasma (PRP) therapy from 80mL of whole blood, second dose of PRP (160mL whole blood) 6 weeks later; Hair regrowth was observed and hair loss stabilized after two doses of PRP treatment; Complete recovery after 6 courses of PRP treatment n = 1 44 M SARS-CoV2 infection followed by vaccination 3 months later Patches of scalp hair loss following first dose; Diffuse hair loss (scalp, eyelashes, bear hair, eyebrows) following second dose Facial and scalp hair regrowth 2 weeks after second dose followed by subsequent Marie Antoinette syndrome 3 days after regrowth. New-onset arm and lower leg hair loss n = 1 33 F Intralesional and topical corticosteroids 1-month follow-up to treatment revealed stable lesions and signs of regrowth n = 2 1: 29 M 2: 26 F 1: (AZD1222) 2:(BNT162b2) 1: AA 2: AA 1: 1 week after 2nd dose 2: 2 weeks after 2nd dose 1: PAA 2: PAA→ AAU 1: Balding patches on scalp 2: Initial diffused hair loss on scalp and body, progressing to areas of eyebrows and eyelash 1 Failed: pulse steroid therapy 2 Failed: pulse steroid therapy n = 2 1: 23 F 2: 26 F 1: (AZD1222) 2: (AZD1222) 1: N/A 2: AA 1: 1 week after 1st dose 2: 2 weeks after 2nd dose 1: PAA→AAU 2: PAA→ AAT 1: Myalgia and local hair scalp, progressing to entire loss of hair in scalp and eyebrows after 3 weeks 2: Patchy hair loss in scalp progressing to total hair loss in scalp after 1 month 1: Systemic cortisone (oral prednisone, 300 mg) for three months 2: Systemic cortisone (oral prednisone, 300 mg) for three months n = 5 4 F: Mean Age 32.4 1 M: 31y 2 patients: (BNT162b2) 3 patients: (mRNA-1273) n = 9 Mean Age: 35.9 1:33 F 2:57 F 3: 62 F 4: 28 F 5: 29 F 6: 22 M 7 :15 M 8: 61 M 9: 16 M 1:mRNA-1273 2: BNT162b2 3:mRNA-1273 4: BNT162b2 5: BNT162b2 6: BNT162b2 7: BNT162b2 8: BNT162b2 9: BNT162b2 1: N/A 2: remote history AA 3: remote Hx AA 4: AA, Hashimoto thyroiditis 5: Elevated levels of thyroglobulin antibody and thyroid peroxidase Antibody 6: Elevated thyroid antibody, normal thyroid function Tests 7: NA 8: Joint pain hydroxychloroquine 9: NA 1: 2 months after 2nd dose 2: 4 months after 2nd dose 3: 2 months after 2nd dose 4: 1 week after 2nd dose 5: 1 week after 2nd dose 6: 1 month after 2nd dose 7: Within 1 week after 2nd dose 8: 2 weeks after 1st dose 9: Within 1–2 weeks after 1st dose 1: PAA 2: AAT 3: AAU 4: AAU 5: PAA 6: PAA 7: PAA 8: AAT 9: PAA 1: Brother AA 7: Grandmother with Hashimoto thyroiditis, sister w/ elevated thyroid antibody 1: Large patches of nonscarring alopecia with foci of hair regrowth 2: widespread nonscarring alopecia of scalp with foci of hair regrowth 3: alopecia universalis 4: Alopecia universalis 5: Two patches of nonscarring alopecia of the scalp with areas of regrowth 6: Patches of nonscarring alopecia; 30% hair loss from scalp, 80% hair loss from beard 7: Two patches of nonscarring alopecia of the scalp 8: Alopecia totalis 9: Patches of nonscarring alopecia with 70% loss of scalp hair; sparse eyebrows and eyelashes 1: 4 treatments intralesional triamcinolone (ILTACT), pimecrolimus 1% cream, clobetasol 0.05%foam, subsequent tofacitinib citrate 5 mg 2: Failed: attempted trials tofacitinib 2%/clobetasol 0.05% ointment/clobetasol solution compounded with little improvement Subsequent Tx: tofacitinib citrate 5 mg 3: tofacitinib citrate 10 mg 2x/day, bimatoprost 0.03% eye drops 4: Failed: PRP therapy (little improvement) Subsequent: tofacitinib citrate 10 mg 2x/day 5: NA previous, subsequent ILTAC 6: Failed previous: ILTAC subsequent Tofacitinib citrate 10 mg twice a day 7: ILTAC 8: Pending possible trial of oral tofacitinib citrate 9: Failed: ILTAC Subsequent: Tofacitinib citrate 10 mg twice a day n = 3 4: 41 F 5: 24 M 6: 21 F 4: 1st dose BNT162b2 5: 1st dose BNT162b2 6: 1st dose mRNA-1273 5: Previous episodes of AA in pediatric age. 6: Allergic Asthma 4: 1 week after dose 5: 1 week after dose 6: 2 weeks after dose 4: PAA 5: PAA 6: PAA 4:Patchy (multiple patches) SALT: 26; Complete regrowth in 3 months 5:AA totalis SALT: 100; Alopecia universalis. 5: Intramuscular triamcinolone 40 mg/dL every 4 weeks for 3 sessions + clobetasol propionate 0.05% under occlusion 5 times/week 6:3 sessions of monthly injection of intralesional triamcinolone 10 g/mL n = 3 1: 27 F 2: 51 F 5: 59 M Booster (3rd dose) (BNT162b2, Sinopharm, and AZD1222) 1: AAU, Polycystic Ovary, COVID-19 2: N/A 3: N/A 1: 8 days after dose 2: 3 days after dose 5: 17 days after dose 1: AAU 2: AAU 5: AAU 1:Alopecia universalis 5:Alopecia universalis 1: Mesotherapy and pulses of dexamethasone and Clobetasol propionate 0.5% topical 5: Mesotherapy and pulses of dexamethasone and Clobetasol propionate 0.5% topical n = 3 1: 76 F 2: 59 F 3: 29 F 1: BNT162b2 2: AZD1222 3: AZD1222 1: AA 2: AA, autoimmune thyroiditis 3: AA 1: 2 weeks 2: 3 weeks 3: 2 weeks 1: AA 2: AA 3: AA 1: Widespread hair loss of scalp 2: Single oval bald patch at vertex 3: Generalized hair loss of scalp 1: topical steroids 2: topical steroids, oral Vitamin D 3: steroids n = 24 (20 F, 4 M) Mean Age: 39.1 15 with 2–3 doses BNT162b2 5 with 2 doses mRNA-1273 4 with 2 doses AZD1222 12 with Autoimmune History 9 with Hashimoto thyroiditis 2 with Celiac disease 1 with Connective tissue disease BNT162b2- 5.7 weeks mRNA-1273- 6.4 weeks AZD1222- 2.2 weeks PAA- (n = 14) AAT (n = 6) AAU (n = 4) n = 2 1–74 M 2–37 M 1- Sinopharm 1st dose 2- Sinopharm 2nd dose 1: 2 days 2: 6 days 1: PAA 2:PAA→AAT n = 3 1–33 F 2–27 M 3–32 M 1–3 doses BNT162b2 2-2 doses BNT162b2 3-2 doses mRNA-1273 1: 2 weeks after first dose, exacerbated after second dose 2: 2 weeks after second dose 3: 2 weeks after first dose 1: AA 2: AA 3: AA 1: near complete, widespread loss of scalp hair 3 months following second dose (SALT increase 33) 2: Patchy Scalp Hair Loss 3: Patchy Scalp Hair loss n = 2 1–42 M 2–18 M 1:3 doses BNT162b2 2: 2 doses BNT162b2 1: AA 2: PAA 1: 4 weeks after second dose, worsened after third dose 2: 20 days after first dose, worsened progressively after second dose 1: AT 2: AT 1: complete loss of whole scalp hairs 2: pre-existing AA patches being treated, experienced worsening of patches being treated following first dose; after second dose, widespread hair loss on whole scalp, positive pull test 1: High potency steroids 2: High potency steroids ChAdOx1 nCoV-19 = AZD1222 = AstraZeneca Recombinant Vaccine mRNA-1273 = Spikevax®= Moderna mRNA BNT162b2 = Comirnaty®= Pfizer BioNTech mRNA MVC-COV1901 = Medigen Recombinant Vaccine Sinopharm = CoronaVac®= inactivated virus M Male, F Female, PAA Patchy alopecia areata, AAT Alopecia areata totalis, AAU Alopecia areata universalis, AA Alopecia areata, N/A Not applicable, SALT The severity of alopecia tool